Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

James S. ButlerAlnylam Pharmaceuticals, Cambridge, MA, USA,

Amy ChanAlnylam Pharmaceuticals, Cambridge, MA, USA, Correspondence[email protected]

Susete CostelhaInstituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, ;Molecular Neurobiology, IBMC – Institute for Molecular and Cell Biology Porto, Porto, PortugalCorrespondence[email protected]

Shannon FishmanAlnylam Pharmaceuticals, Cambridge, MA, USA, Correspondence[email protected]

Jennifer L. S. WilloughbyAlnylam Pharmaceuticals, Cambridge, MA, USA, Correspondence[email protected]

Todd D. BorlandAlnylam Pharmaceuticals, Cambridge, MA, USA, Correspondence[email protected]

Stuart MilsteinAlnylam Pharmaceuticals, Cambridge, MA, USA,

Donald J. FosterAlnylam Pharmaceuticals, Cambridge, MA, USA,

Paula GonçalvesInstituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, ;Molecular Neurobiology, IBMC – Institute for Molecular and Cell Biology Porto, Porto, Portugal

Qingmin ChenAlnylam Pharmaceuticals, Cambridge, MA, USA,

June QinAlnylam Pharmaceuticals, Cambridge, MA, USA,

Brian R. BettencourtAlnylam Pharmaceuticals, Cambridge, MA, USA,

Dinah W. SahAlnylam Pharmaceuticals, Cambridge, MA, USA,

Rene AlvarezAlnylam Pharmaceuticals, Cambridge, MA, USA,

Kallanthottathil G. RajeevAlnylam Pharmaceuticals, Cambridge, MA, USA,

Muthiah ManoharanAlnylam Pharmaceuticals, Cambridge, MA, USA,

Kevin FitzgeraldAlnylam Pharmaceuticals, Cambridge, MA, USA,

Rachel E. MeyersAlnylam Pharmaceuticals, Cambridge, MA, USA,

Saraswathy V. NochurAlnylam Pharmaceuticals, Cambridge, MA, USA,

Maria J. SaraivaInstituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, ;Molecular Neurobiology, IBMC – Institute for Molecular and Cell Biology Porto, Porto, Portugal

Tracy S. ZimmermannAlnylam Pharmaceuticals, Cambridge, MA, USA,

show all

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date